Abbott Tries a Crash Diet

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Another day, another round of layoffs at a pharmaceutical company. Abbott Labs (NYSE: ABT  ) joined Wyeth (NYSE: WYE  ) , Schering-Plough (NYSE: SGP  ) , and Amgen (Nasdaq: AMGN  ) , among others, in cutting back its workforce.

Abbott's cuts are particularly interesting because the company doesn't seem to be in trouble, like the other drugmakers mentioned are. Wyeth made cuts in large part because its heartburn medication, Protonix, started receiving generic competition from Teva Pharmaceutical (Nasdaq: TEVA  ) . Schering and Merck (NYSE: MRK  ) are struggling after the Enhance trial slowed the growth of Vytorin sales. And Amgen's anemia franchise has been anemic of late.

Abbott, on the other hand, posted 15% year-over-year sales growth last quarter. Sales of diagnostic tests, the division from which the 1,000 jobs will be cut, were up more than 17%. The company is clearly trying to increase margins, even in good times, and that's definitely something investors should be looking for in a company.

The cuts will result in pre-tax charges of about $370 million over the next several years, with almost 40% of that sum coming in the third quarter. After the plan is complete, Abbott should see savings of $150 million per year -- not a bad return on its investment.

Abbott had planned to sell the diagnostic-test division to General Electric (NYSE: GE  ) , but the deal fell through last year. In the end, I think that was a good thing for the health-care conglomerate. The tests give the company diversity, which should provide stability if one of its other divisions slips up.

Abbott hasn't gotten much love from investors this year, but this move should give stockholders more confidence that management is doing everything it can to improve the bottom line.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial subscription

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a right-sized disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 712959, ~/Articles/ArticleHandler.aspx, 10/27/2016 8:47:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
ABT $40.29 Up +0.33 +0.83%
Abbott Laboratorie… CAPS Rating: *****
AMGN $160.57 Up +1.58 +0.99%
Amgen CAPS Rating: ****
GE $28.63 Down -0.24 -0.83%
General Electric CAPS Rating: ****
MRK $61.29 Up +0.42 +0.69%
Merck and Co. CAPS Rating: ****
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****
TEVA $43.15 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***